SHPH SEC Filings - Shuttle Pharmaceuticals Holdings, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

1757499

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Shuttle Pharmaceuticals Holdings, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

September 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2025 SHUTTLE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporati
August 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 OR ☐ Transition Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-41488 SHUTTLE PHA
August 11, 2025	424B3	Shuttle Pharmaceuticals Holdings, Inc. 1,180,877 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Under the Securities Act of 1933, as amended Registration No.
August 5, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 Shuttle Pharmaceuticals Holdings, Inc.
August 5, 2025	S-1	As filed with the Securities and Exchange Commission on August 4, 2025 As filed with the Securities and Exchange Commission on August 4, 2025 Registration No.
July 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 SHUTTLE PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation
June 25, 2025	EX-99.2	Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market Exhibit 99.2 Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market GAITHERSBURG, Md., June 24, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today ann
June 25, 2025	EX-10.2	Registration Rights Agreement, dated June 20, 2025 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (“Agreement”) is entered into as of the 20th day of June, 2025 by and among Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and the purchasers from time to time party hereto (each, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase
June 25, 2025	EX-10.3	Form of Pre-Funded Warrant Exhibit 10.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a
June 25, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation
June 25, 2025	EX-99.1	Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market Exhibit 99.1 Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market GAITHERSBURG, Md., June 20, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today ann
June 25, 2025	EX-10.1	Securities Purchase Agreement, dated June 20, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 20, 2025, between Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, including its successors and assigns, an “Purchaser” and collectively the “Purchasers”). RECITALS A. The Compa
May 28, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation)
May 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 SHUTTLE PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation)
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 OR ☐ Transition Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-41488 SHUTTLE PH
May 6, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) ☒ Def
April 22, 2025	PRER14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) ☐ Def
April 21, 2025	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
April 21, 2025	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) ☒ Def
April 21, 2025	EX-99.1	Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 Company to conduct 1x1 meetings on April 24, 2025 Exhibit 99.1 Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 Company to conduct 1x1 meetings on April 24, 2025 GAITHERSBURG, Md., April 21, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treat
April 10, 2025	PRER14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) ☐ Def
April 10, 2025	EX-99.1	Shuttle Pharma Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Dia Exhibit 99.1 Shuttle Pharma Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic program Dr. Alan Kozikowski, internationally acclaimed pioneer in the discovery of a critical PSMA targeting ligand for clinical
April 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 SHUTTLE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
April 4, 2025	EX-10.1	Consulting Agreement, dated April 3, 2025, between Shuttle Pharmaceuticals Holdings, Inc. and IR Agency LLC. Exhibit 10.1 CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to Shuttle Pharmaceuticals Holdings Inc (“you,” “Client” or “Company”) as more fully described in this agreement (the “Agreement”). This Agreement sets forth the terms and conditions pursuant to which Company engages Consultant to provide such services. 1. Consulting
April 4, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation
March 31, 2025	EX-10.1	Form of Employment Agreement, dated March 31, 2025, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo. Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”), originally dated June 28, 2019 (the “Original Employment Agreement”), is entered into as of the 31st day of March 2025, by and between Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and Anatoly Dritschilo, M.D., an individual residing at the addr
March 31, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
March 31, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) ☒ Def
March 25, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
March 25, 2025	EX-1.1	Consulting Agreement, dated March 21, 2025, by and between Shuttle Pharmaceuticals Holdings, Inc. and Bowery Consulting Group Inc. Exhibit 1.1 CONSULTING SERVICES AGREEMENT THIS AGREEMENT DATED AS OF March 21st 2025 BETWEEN: Shuttle Pharmaceuticals Holdings Inc. A proprietorship registered in the State of Maryland (hereinafter referred to as the “Firm”) -and- Bowery Consulting Group Inc. A corporation registered in the State of Florida (hereinafter referred to as the “Consultant”) A. RECITALS WHEREAS the Firm carries on busin
March 19, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) ☐ Def
March 13, 2025	EX-99.2	Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering Exhibit 99.2 Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering GAITHERSBURG, Md., March 13, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the closing of its previously annou
March 13, 2025	EX-1.1	Underwriting Agreement, dated March 12, 2025, by and between Shuttle Pharmaceuticals Holdings, Inc. and WestPark Capital, Inc. Exhibit 1.1 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. UNDERWRITING AGREEMENT March 12, 2025 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 As Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, SHUTTLE PHARMACEUTICALS HOLDINGS, INC., a corporation formed under the laws of the State of Delaware (the “Comp
March 13, 2025	424B3	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 1,340,921 Shares of Common Stock 17,825,746 Pre-Funded Warrants to Purchase 17,825,746 Shares of Common Stock 17,825,746 Shares of Common Stock Underlying the Pre-Funded Warrants Filed pursuant to Section 424(b)(3) Registration No. 333-284889 PROSPECTUS SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 1,340,921 Shares of Common Stock 17,825,746 Pre-Funded Warrants to Purchase 17,825,746 Shares of Common Stock 17,825,746 Shares of Common Stock Underlying the Pre-Funded Warrants This is a firm commitment underwritten offering of 1,340,921 shares (the “Shares”) of common stock, par val
March 13, 2025	EX-99.1	Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering Exhibit 99.1 Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering GAITHERSBURG, Md., March 12, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the pricing of an underwritten publ
March 13, 2025	8-K	Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
March 12, 2025	EX-99.1	Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activities Exhibit 99.1 Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activities GAITHERSBURG, Md., March 12, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage sp
March 12, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
March 12, 2025	EX-10.1	Consulting Agreement, dated March 11, 2025 (incorporated by reference to 8-K filed March 12, 2025) Exhibit 10.1 CONSULTIng AGREEMENT THIS AGREEMENT (the “Agreement”) is dated effective March 11, 2025 (the “Effective Date”). BETWEEN: SHUTTLE PHARMACEUTICALS a corporation having an office located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879 (the “Company”) AND: NUMBER 2 CAPITAL CORP., a corporation with its principal residence located at 5630 Olympic Street, Vancouver, British Col
March 6, 2025	CORRESP	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (240) 430-4212 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (240) 430-4212 March 6, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 File No. 333-284889 Acceleration Request Requested Date: Friday, March 7,
March 6, 2025	CORRESP	WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 March 6, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 File No. 333-284889 Acceleration Request Requested Date: Friday, March 7, 2025 Requested Time: 4:30 PM Ea
March 5, 2025	EX-4.9	Form of Pre-Funded Warrant (incorporated by reference to S-1/A filed March 5, 2025) Exhibit 4.9 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f
March 5, 2025	S-1/A	As filed with the Securities and Exchange Commission on March 4, 2025. As filed with the Securities and Exchange Commission on March 4, 2025. Registration No. 333-284889 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State or other jurisdictio
March 5, 2025	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. FORM OF UNDERWRITING AGREEMENT March [*], 2025 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 As Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, SHUTTLE PHARMACEUTICALS HOLDINGS, INC., a corporation formed under the laws of the State of Delaware (
March 5, 2025	EX-3.6	Third Amended and Restated By-Laws. Exhibit 3.6 SHUTTLE PHARMAceuticals holdings, inc. Incorporated Under the Laws of the State of Delaware THIRD AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES Shuttle Pharmaceuticals Holdings, Inc. (the “Corporation”) shall maintain a registered office in the State of Delaware. The Corporation may also have other offices at such places, either within or without the State of Delaware, as the Board of
February 28, 2025	EX-10.2	Revolving Note, dated February 28, 2025, between Shuttle Pharmaceuticals Holdings, Inc. and Bowery Consulting Group Inc. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed February 28, 2025). Exhibit 10.2 REVOLVING NOTE February 28, 2025 $2,000,000 FOR VALUE RECEIVED, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“Borrower”) HEREBY PROMISES TO PAY to the order of Bowery Consulting Group Inc. (together with its successors, participants and assigns, “Lender”), in lawful money of the United States of America and in immediately available funds, the principal amount of TWO
February 28, 2025	EX-10.1	Revolving Loan Agreement, dated February 28, 2025, between Shuttle Pharmaceuticals Holdings, Inc. and Bowery Consulting Group Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed February 28, 2025). Exhibit 10.1 REVOLVING LOAN AGREEMENT This Revolving Loan Agreement (this “Agreement”) is dated as of February 28, 2025 between Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Borrower”), and the purchaser identified on the signature page hereto (including its successors and assigns, the “Lender”). WHEREAS, Borrower wishes to obtain Loans from time to time from Lender in an ag
February 28, 2025	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
February 27, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
February 27, 2025	EX-10.1	Amendment Agreement, dated February 26, 2025, between Shuttle Pharmaceuticals Holdings, Inc. and Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed February 27, 2025). Exhibit 10.1 Amendment Agreement This Amendment Agreement (this “Amendment”), dated as of February 26, 2025, is made by and between Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, in its capacity as the registered holder (the “Holder”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”) and each Guarantor signatory hereto. WHEREAS, the Company and the
February 27, 2025	424B3	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 395,574 Shares of Common Stock 2,555,246 Pre-Funded Warrants to Purchase up to 2,555,246 Shares of Common Stock 2,950,820 Common Warrants to Purchase up to 2,950,820 Shares of Common Stock 2,555,246 Shares of Co Filed Pursuant to Section 424(b)(3) Registration No. 333-282231 Prospectus Supplement No. 1 (To Prospectus Dated October 29, 2024) SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 395,574 Shares of Common Stock 2,555,246 Pre-Funded Warrants to Purchase up to 2,555,246 Shares of Common Stock 2,950,820 Common Warrants to Purchase up to 2,950,820 Shares of Common Stock 2,555,246 Shares of Common Stock Underlyi
February 27, 2025	EX-1	CONSENT OF FORVIS MAZARS, LLP Consent of Independent Registered Public Accounting Firm We consent to the inclusion in this Prospectus Supplement No.
February 27, 2025	EX-1	CONSENT OF FORVIS MAZARS, LLP Consent of Independent Registered Public Accounting Firm We consent to the inclusion in this Prospectus Supplement No.
February 27, 2025	EX-1	CONSENT OF FORVIS MAZARS, LLP Consent of Independent Registered Public Accounting Firm We consent to the inclusion in this Prospectus Supplement No.
February 27, 2025	424B3	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 1,464,268 Shares of Common Stock Issuable Upon Conversion of 14.5% Senior Secured Convertible Notes Up to 329,461 Shares of Common Stock Issuable Upon Exercise of Warrants Filed Pursuant to Section 424(b)(3) Registration No. 333-284286 Prospectus Supplement No. 1 (To Prospectus Dated January 23, 2025) SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 1,464,268 Shares of Common Stock Issuable Upon Conversion of 14.5% Senior Secured Convertible Notes Up to 329,461 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus supplement No. 1 updates, amends and
February 27, 2025	424B3	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants Filed Pursuant to Section 424(b)(3) Registration No. 333-269414 Prospectus Supplement No. 4 (To Prospectus Dated February 1, 2023) SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus supplement No. 4 updates, amends and
February 26, 2025	EX-21	List of Subsidiaries* Exhibit 21 List of Subsidiaries Shuttle Pharmaceuticals, Inc., a Maryland corporation Shuttle Diagnostics, Inc., a Maryland corporation
February 26, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
February 26, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41488 Shuttle Pharma
February 26, 2025	EX-10.1	Press Release dated February 26, 2025 Exhibit 10.1 Shuttle Pharma Provides Corporate Update and Reports 2024 Results GAITHERSBURG, Md., February 26, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in
February 13, 2025	S-1	As filed with the Securities and Exchange Commission on February 12, 2025. As filed with the Securities and Exchange Commission on February 12, 2025. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State or other jurisdiction of incorporation or org
February 13, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
January 28, 2025	EX-10.1	Change Order, dated January 23, 2025, between Shuttle Pharmaceuticals, Inc. and Theradex Systems, Inc. (incorporated by reference to Exhibit 10.1 to the Current report on Form 8-K filed January 28, 2025). Exhibit 10.1 Portions of this agreement have been redacted pursuant to Item 601(b)(10(iv). Redactions are indicated with “[***]” Change Order #1 to Work Order #3 Theradex Systems, Inc. (hereinafter “Theradex Oncology”) to assist Shuttle Pharmaceuticals, Inc. (hereinafter “Shuttle”) with the Scope of Work associated with: Phase 2 Study of IPdR as a Radiation Sensitizing Agent During Radiotherapy in
January 28, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporat
January 24, 2025	424B3	Up to 1,464,268 Shares of Common Stock Issuable Upon Conversion of 14.5% Senior Secured Convertible Notes Up to 329,461 Shares of Common Stock Issuable Upon Exercise of Warrants Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-284286 PROSPECTUS Up to 1,464,268 Shares of Common Stock Issuable Upon Conversion of 14.5% Senior Secured Convertible Notes Up to 329,461 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to the resale from time to time of (i) up to 1,464,268 shares of common stock underlying $831,579 in convertible not
January 22, 2025	RW	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (240) 430-4212 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (240) 430-4212 January 21, 2025 Via EDGAR Ms. Jessica Dickerson U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 File No. 333-278535 Dear Ms. Dickerson: Pursuant
January 21, 2025	EX-99.1	Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Exhibit 99.1 Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma GAITHERSBURG, Md., January 21, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with r
January 21, 2025	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporat
January 21, 2025	CORRESP	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (240) 430-4212 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (240) 430-4212 January 21, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 File No. 333-284286 Acceleration Request Requested Date: Thursday, Jan
January 15, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Shuttle Pharmaceuticals Holdings, Inc.
January 15, 2025	S-1	As filed with the Securities and Exchange Commission on January 14, 2025. As filed with the Securities and Exchange Commission on January 14, 2025. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State or other jurisdiction of incorporation or orga
January 7, 2025	EX-99.1	Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 Exhibit 99.1 Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 GAITHERSBURG, Md., January 7, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced t
January 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 SHUTTLE PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
December 19, 2024	EX-10.1	Sponsored Research Agreement, dated December 16, 2024, by and among Shuttle Pharmaceuticals Holdings, Inc., the Regents of the University of California and Dr. Robert Favell (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed December 19, 2024). Exhibit 10.1 Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. Such information is identified with “[***]” where such information has been omitted. SPONSORED RESEARCH AGREEMENT This Sponsored Research Agreement (“Agreement”), effective as of the date of last signature hereto (“Effect
December 19, 2024	EX-99.1	Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program Exhibit 99.1 Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program GAITHERSBURG, Md., December 19, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with rad
December 19, 2024	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 16, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
November 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 SHUTTLE PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
November 26, 2024	EX-99.1	DRAFT – GOAL TO RELEASE AT TUESDAY, NOVEMBER 26 @ 9AM ET Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient Exhibit 99.1 DRAFT – GOAL TO RELEASE AT TUESDAY, NOVEMBER 26 @ 9AM ET Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient GAITHERSBURG, Md., November 26, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage special
November 13, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
November 13, 2024	EX-99.1	Shuttle Pharma Provides Third Quarter 2024 Corporate Update Exhibit 99.1 Shuttle Pharma Provides Third Quarter 2024 Corporate Update GAITHERSBURG, Md., November 13, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connec
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41488 SHUTT
November 1, 2024	EX-4.2	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K dated October 31, 2024) Exhibit 4.2 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: [] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
November 1, 2024	EX-4.1	Form of Common Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K dated October 31, 2024) Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT Shuttle Pharmaceuticals Holdings, INC. Warrant Shares: [ ] Initial Dated Exercisable Date: [ ]I Issuance Date: [ ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [NAME OF HOLDER] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
November 1, 2024	EX-1.1	Placement Agency Agreement, dated as of October 29, 2024, by and among Shuttle Pharmaceuticals Holdings, Inc. and A.G.P./Alliance Global Partners and Boustead Securities, LLC, as placement agents (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K dated October 31, 2024). Exhibit 1.1 October 29, 2024 Shuttle Pharmaceuticals Holdings, Inc. Attention: Dr. Anatoly Dritschilo, M.D. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 Dear Dr. Dritschilo: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.”), Boustead Securities, LLC (“Boustead” and together with A.G.P., the “Placement Agents”) and Shuttle Pharmac
November 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 (October 29, 202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 (October 29, 2024) SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdi
November 1, 2024	EX-99.1	Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patient
November 1, 2024	EX-10.1	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K dated October 31, 2024). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 29, 2024, between Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the ter
October 31, 2024	424B4	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 395,574 Shares of Common Stock 2,555,246 Pre-Funded Warrants to Purchase up to 2,555,246 Shares of Common Stock 2,950,820 Common Warrants to Purchase up to 2,950,820 Shares of Common Stock 2,555,246 Shares of Co Filed Pursuant to Rule 424(b)(4) PROSPECTUS Registration No. 333-282231 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 395,574 Shares of Common Stock 2,555,246 Pre-Funded Warrants to Purchase up to 2,555,246 Shares of Common Stock 2,950,820 Common Warrants to Purchase up to 2,950,820 Shares of Common Stock 2,555,246 Shares of Common Stock Underlying the Pre-Funded Warrants 2,950,820 Shares of Common Stock
October 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 SHUTTLE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporat
October 29, 2024	EX-99.1	Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Exhibit 99.1 Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma GAITHERSBURG, Md., October 29, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT
October 28, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporat
October 28, 2024	EX-99.1	Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma Exhibit 99.1 Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma GAITHERSBURG, Md., October 28 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therap
October 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 SHUTTLE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporat
October 28, 2024	EX-99.2	Investor Presentation Exhibit 99.2
October 28, 2024	EX-99.1	Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 Exhibit 99.1 Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 ROCKVILLE, MD., October 28, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief Execut
October 25, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporat
October 25, 2024	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 October 25, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1, as amended File No: 333-282231 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Se
October 25, 2024	CORRESP	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (240) 430-4212 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (240) 430-4212 October 25, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1, as amended File No. 333-282231 Acceleration Request Requested Date: T
October 18, 2024	S-1/A	As filed with the Securities and Exchange Commission on October 18, 2024 As filed with the Securities and Exchange Commission on October 18, 2024 Registration No.
October 18, 2024	EX-1.1	Form of Placement Agency Agreement Exhibit 1.1 [], 2024 Shuttle Pharmaceuticals Holdings, Inc. Attention: Dr. Anatoly Dritschilo, M.D. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 Dear Dr. Dritschilo: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.”), Boustead Securities, LLC (“Boustead” and together with A.G.P., the “Placement Agents”) and Shuttle Pharmaceuticals
October 18, 2024	EX-10.61	Form of Securities Purchase Agreement Exhibit 10.61 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●] 2024, between Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and
October 18, 2024	EX-4.7	Form of Pre-Funded Warrants Exhibit 4.7 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: [] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
October 18, 2024	EX-4.6	Form of Common Warrants Exhibit 4.6 FORM OF COMMON STOCK PURCHASE WARRANT Shuttle Pharmaceuticals Holdings, INC. Warrant Shares: [ ] Initial Dated Exercisable Date: [ ]I Issuance Date: [ ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [NAME OF HOLDER] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
October 18, 2024	CORRESP	Shuttle Pharmaceuticals Holdings, Inc. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 Shuttle Pharmaceuticals Holdings, Inc. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 October 18, 2024 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Attn: Ms. Jessica Dickerson Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 Filed September 20, 2024 File No. 333-282231 Ladies and Gentle
October 18, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Shuttle Pharmaceuticals Holdings, Inc.
October 17, 2024	EX-10.3	Form of Common Warrants (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on October 17, 2024). Exhibit 10.3 Form of Common Stock Warrant NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABS
October 17, 2024	EX-10.1	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on October 17, 2024). Exhibit 10.1 Form of SECURITIES Purchase Agreement This Securities Purchase Agreement, dated as of October [*], 2024 (this “Agreement”), is entered into by and among Shuttle Pharmaceuticals Holdings Inc., a Delaware corporation (the “Company”), and the persons and entities listed on the signature page hereto (each an “Investor” and, collectively, the “Investors”). RECITALS A. On the terms and subj
October 17, 2024	EX-10.2	Form of Senior Secured Convertible Notes (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on October 17, 2024). Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
October 17, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporat
September 20, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Shuttle Pharmaceuticals Holdings, Inc.
September 20, 2024	S-1	As filed with the Securities and Exchange Commission on September 19, 2024 As filed with the Securities and Exchange Commission on September 19, 2024 Registration No.
September 16, 2024	424B3	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants Filed Pursuant to Section 424(b)(3) Registration No. 333-269414 Prospectus Supplement No. 3 (To Prospectus Dated February 1, 2023) SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus supplement No. 3 updates, amends and
September 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 SHUTTLE PHARMA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpor
September 10, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
September 10, 2024	EX-10.1	Form of Promissory Note, dated September 4, 2024, between Shuttle Pharmaceuticals and Anatoly Dritschilo. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed September 10, 2024). Exhibit 10.1 PROMISSORY NOTE $250,000.00 September 4,2024 Maryland, United States For value received, Shuttle Pharmaceutical Holdings, Inc., a Delaware company (the “Company”), promises to pay to Anatoly Dritschilo (the “Holder”), the principal sum of $250,000.00 (the “Principal”). Interest shall accrue from the date of this Promissory Note (this “Note”) on the unpaid principal amount at a rate eq
September 4, 2024	EX-21	List of Subsidiaries. Exhibit 21 List of Subsidiaries Shuttle Pharmaceuticals, Inc., a Maryland corporation Shuttle Diagnostics, Inc., a Maryland corporation
September 4, 2024	EX-99.1	Shuttle Pharma Provides Second Quarter 2024 Corporate Update Exhibit 99.1 Shuttle Pharma Provides Second Quarter 2024 Corporate Update GAITHERSBURG, Md., September 4, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the fi
September 4, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-
September 4, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ Quarterly Report UNDER Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report UNDER Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-41488 SH
September 4, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report UNDER Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR ☐ Transition Report UNDER Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-41488 SHUTTLE PHARMACEUTICALS
September 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 4, 2024 SHUTTLE PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 4, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
August 28, 2024	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 27, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporati
August 28, 2024	EX-99.1	Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement GAITHERSBURG, Md., August 28, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it has r
August 26, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 21, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporati
August 26, 2024	EX-99.1	Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) Exhibit 99.1 Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) GAITHERSBURG, Md., August 26, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today reports that i
August 14, 2024	EX-10.2	Master Services Agreement, dated November 1, 2018, between Shuttle Pharmaceuticals, Inc. and Theradex Systems Inc. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed August 14, 2024). Exhibit 10.2
August 14, 2024	EX-10.1	Work Order, dated August 8, 2024, between Shuttle Pharmaceuticals, Inc. and Theradex Systems, Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on August 14, 2024). Exhibit 10.1 Portions of this agreement have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. Redactions are indicated with “[***].” Work Order #3 Theradex Systems, Inc. (hereinafter “Theradex Oncology”) to assist Shuttle Pharmaceuticals, Inc. (hereinafter “Shuttle”) with the Scope of Work associated with: Phase 2 Study of IPdR as a Radiation Sensitizing Agent During Radiotherapy i
August 14, 2024	EX-99.1	Shuttle Pharma Ready to Enroll patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Exhibit 99.1 Shuttle Pharma Ready to Enroll patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma GAITHERSBURG, Md., August 14, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy
August 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 SHUTTLE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
August 13, 2024	NT 10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 Commission File Number 001-41488 NOTIFICATION OF LATE FILING (Check One): U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 Commission File Number 001-41488 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 11-K ☐ Form 20-F ☒ Form 10-Q ☐ Form N-SAR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ Transition Report on For
August 7, 2024	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Other Events, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 5, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
August 7, 2024	EX-10.1	Amendment Agreement, dated August 6, 2024, between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on August 7, 2024). Exhibit 10.1 Amendment Agreement This Amendment Agreement (this “Amendment”), dated as of August 6, 2024, is made by and between Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, in its capacity as the registered holder (the “Holder”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”) and each Guarantor signatory hereto. WHEREAS, the Company and the Bu
August 7, 2024	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation, effective August 13, 2024 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on August 7, 2024). Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SHUTTLE PHARMACEUTICALS HOLDINGS, INC. The undersigned, being the Chief Executive Officer of Shuttle Pharmaceuticals Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby amend and certify as follows: 1. That the name of the Corporatio
August 1, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 31, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation
July 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 SHUTTLE PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation
June 20, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) ☒ Def
June 18, 2024	EX-10.1	Employment Agreement, dated June 13, 2024, between Shuttle Pharmaceuticals Holdings, Inc. and Timothy J. Lorber (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 18, 2024). Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), effective as of the 10th day June, 2024, is entered into by and between Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and Timothy J. Lorber, CPA, an individual residing at the address set forth on Schedule A hereto (the “Executive”). INTRODUCTION WHEREAS, the Company is in the business
June 18, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation
June 18, 2024	EX-99.1	Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory Exhibit 99.1 Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory GAITHERSBURG, Md., June 18, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated w
June 10, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) ☐ Def
May 22, 2024	EX-99.1	Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 Exhibit 99.1 Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 ROCKVILLE, Md., May 22, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo
May 22, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation)
May 14, 2024	EX-99.1	Shuttle Pharma Provides First Quarter 2024 Corporate Update Exhibit 99.1 Shuttle Pharma Provides First Quarter 2024 Corporate Update GAITHERSBURG, Md., May 14, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing o
May 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 SHUTTLE PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation)
May 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report UNDER Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report UNDER Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-41488 SHUTTLE PHARMACEUTICAL
April 29, 2024	EX-99.1	Investor Presentation Exhibit 99.1
April 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 SHUTTLE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
April 23, 2024	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
April 23, 2024	EX-99.1	Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 Exhibit 99.1 Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 GAITHERSBURG, MD., April 23, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy
April 5, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Shuttle Pharmaceuticals Holdings, Inc.
April 5, 2024	S-1	As filed with the U.S. Securities and Exchange Commission on April 5, 2024 As filed with the U.S. Securities and Exchange Commission on April 5, 2024 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Shuttle Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State or other jurisdiction of incorporation or org
March 22, 2024	424B3	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants Filed Pursuant to Section 424(b)(3) Registration No. 333-269414 Prospectus Supplement No. 2 (To Prospectus Dated February 1, 2023) SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus supplement No. 2 updates, amends and
March 22, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
March 22, 2024	EX-99.1	Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update Exhibit 99.1 Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update GAITHERSBURG, Md., March 22, 2024 - Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filin
March 21, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41488 Shuttle Pharma
March 21, 2024	EX-21	List of Subsidiaries (incorporated by reference to Exhibit 21 to the Annual Report on Form 10-K filed on March 21, 2024). Exhibit 21 List of Subsidiaries Shuttle Pharmaceuticals, Inc., a Maryland corporation Shuttle Diagnostics, Inc., a Maryland corporation
March 5, 2024	EX-99.1	Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024 Webcast presentation to take place at 11:25am ET Exhibit 99.1 Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024 Webcast presentation to take place at 11:25am ET ROCKVILLE, MD., March 5, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today
March 5, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
February 13, 2024	EX-10.1	Securities Purchase Agreement, dated February 7, 2024, between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Diagnostics, Inc. and SRO LLC (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on February 13, 2024). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), effective as of February 7, 2024, is made by and between Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company” or “SHPH”), its wholly owned subsidiary, Shuttle Diagnostics, Inc., a Delaware corporation (“Diagnostics” and together with the Company, the “Sellers”), and SRO, LLC,
February 13, 2024	EX-10.2	Placement Agent and Advisory Services Agreement, dated February 7, 2024, between Shuttle Pharmaceuticals Holdings, Inc. and Boustead Securities, LLC (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on February 13, 2024). Exhibit 10.2 PLACEMENT AGENT AND ADVISORY SERVICES AGREEMENT This PLACEMENT AGENT AND ADVISORY SERVICES AGREEMENT (the “Agreement”), dated as of February 7, 2024 (the “Effective Date”), by and between Boustead Securities, LLC (“BSL”), a California limited liability company having its principal offices located at 6 Venture, Suite 395, Irvine, CA 92618 and Shuttle Pharmaceuticals Holdings, Inc., a D
February 13, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of Incorporat
February 13, 2024	EX-99.1	Shuttle Pharma Announces Its Intent to Pursue a Rights Offering Exhibit 99.1 Shuttle Pharma Announces Its Intent to Pursue a Rights Offering ROCKVILLE, Md., February 13, 2024 - Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“SHPH” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), along with its wholly-owned subsidiary, Shuttle D
February 13, 2024	EX-10.3	Offering Deposit Account Agency Agreement, dated February 7, 2024, between Shuttle Pharmaceuticals Holdings, Inc., Boustead Securities, LLC and Sutter Securities Inc. (incorporated by reference to Exhibit 10.3 to the Current Report on Form 10-K filed on February 13, 2024). Exhibit 10.3 OFFERING DEPOSIT ACCOUNT AGENCY AGREEMENT This Offering Deposit Account Agency Agreement (this “Agreement”) dated as of February 7, 2024 by and among Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), having an address at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879, its wholly owned subsidiary, Shuttle Diagnostics, Inc., a Delaware corporation (“Subsidiary” and toge
February 5, 2024	EX-10.1	Asset Purchase Agreement, dated January 30, 2024, by and between Shuttle Pharmaceuticals Holdings, Inc., Alan Kozikowski and Werner Tueckmantel (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on February 5, 2024). Exhibit 10.1 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (“Agreement”) is entered into on January 30, 2024 (“Effective Date”) by and between Shuttle Pharmaceuticals Holdings, Inc. (a.k.a. Shuttle Pharma), a Delaware corporation with an office at 1 Research Court, Suite 450, Rockville, MD 20850 (“Purchaser”), and Alan P. KOZIKOWSKI, with domicile at N 3371 River Drive, Wallace MI 49893,
February 5, 2024	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporat
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 8, 2024 SHUTTLE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 8, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporati
January 8, 2024	EX-99.1	Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Exhibit 99.1 Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma ROCKVILLE, Md., January 8, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”) today announced they have received the ‘Safe to Proceed’ letter from the U.S. Food and Drug Administration (FDA) for the Company’s i
December 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 SHUTTLE PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
December 11, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
December 11, 2023	EX-99.1	Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma Exhibit 99.1 Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma ROCKVILLE, Md., December 11, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”) today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to support the
November 30, 2023	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
November 30, 2023	EX-99.1	Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023 Webcasted presentation to take place at 10:15am ET Exhibit 99.1 Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023 Webcasted presentation to take place at 10:15am ET ROCKVILLE, Md., Nov. 30, 2023 /PRNewswire/ — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation ther
November 14, 2023	EX-99.1	Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update Exhibit 99.1 Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update ROCKVILLE, Md., November 14, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Qu
November 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 SHUTTLE PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpora
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41488 SHUTT
October 30, 2023	EX-99.1	Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement Exhibit 99.1 Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement ROCKVILLE, Md., October 30, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered into
October 30, 2023	EX-10.1	License Agreement, dated October 24, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc. and Georgetown University (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on October 30, 2023). Exhibit 10.1 This Exhibit 10.1 includes certain identified information that has been redacted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Where information has been redacted, it has been so indicated by a “[***]”. LICENSE AGREEMENT between GEORGETOWN UNIVERSITY and SHUTTLE PHARMACEUTICALS HOLDINGS, INC. CONFIDENTIAL GU REF No.: 2018-012 LICENS
October 30, 2023	8-K	Other Events, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 24, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporat
October 20, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) ☒ Def
October 18, 2023	SC 13G/A	SHPH / Shuttle Pharmaceuticals Holdings Inc / AFH Holding & Advisory, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 825693 (CUSIP Number) Amir F. Heshmatpour 17304 Preston Road, Suite 300 Dallas, Texas 75252 (310) 721-4391 With copies to:
October 10, 2023	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 10, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporat
October 10, 2023	EX-99.1	Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference Exhibit 99.1 Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference ROCKVILLE, Md., October 10, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Execut
October 5, 2023	EX-10.1	Consulting Agreement, dated October 1, 2023, between Shuttle Pharmaceuticals Holdings, Inc. and Joseph Armstrong (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on October 5, 2023). Exhibit 10.1 Shuttle Pharmaceuticals, Inc. One Research Court, Suite 450 Rockville, MD 20850 Scientific Advisory Board CONSULTING CONTRACT This Consulting Contract (“Contract’’) is entered into by Shuttle Pharmaceuticals, Inc. (“Company”) and Joseph Armstrong, PhD (“Consultant”) this 1st day of October 2023 which will serve as the Effective Date. This agreement supersedes all prior written or verb
October 5, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 1, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporati
September 25, 2023	EX-99.1	Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma Company remains on track to initiate the clinical trial in Q4 of 2023 Exhibit 99.1 Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma Company remains on track to initiate the clinical trial in Q4 of 2023 ROCKVILLE, Md., September 25, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving th
September 25, 2023	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 25, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorpor
September 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 31, 2023 SHUTTLE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 31, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporati
August 24, 2023	424B3	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants Filed Pursuant to Section 424(b)(3) Registration No. 333-269414 Prospectus Supplement No. 1 (To Prospectus Dated February 1, 2023) SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus supplement No.1 updates, amends and s
August 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 15, 2023 SHUTTLE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 15, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporati
August 15, 2023	EX-99.1	Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update Exhibit 99.1 Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update ROCKVILLE, Md., August 15, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Qua
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report UNDER Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 OR ☐ Transition Report UNDER Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-41488 SHUTTLE PHARMACEUTICAL
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 3, 2023 SHUTTLE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 3, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporatio
August 3, 2023	EX-99.1	Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial Exhibit 99.1 Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial ROCKVILLE, Md., Aug. 3, 2023 /PRNewswire/ — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced
June 16, 2023	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement SHUTTLE PHARMACEUTICALS HOLDINGS, I
June 5, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of Incorporation)
June 5, 2023	EX-10.1	Amendment No. 1 to the Amendment Agreement, dated June 4, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 5, 2023). Exhibit 10.1 Amendment No. 1 to Amendment Agreement This amendment no. 1 (the “Amendment”), dated June 4, 2023, to the Amendment Agreement, originally dated as of May 10, 2023 (the “Amended Agreement”), is made by and between Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, in its capacity as the registered holder (the “Holder”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware
June 5, 2023	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement SHUTTLE PHARMACEUTICALS HOLDINGS, I
May 30, 2023	SC 13G	SHPH / Shuttle Pharmaceuticals Holdings Inc / AFH Holding & Advisory, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 825693 (CUSIP Number) Amir F. Heshmatpour 17304 Preston Road, Suite 300 Dallas, Texas 75252 (310) 721-4391 With copies to: La
May 26, 2023	8-K	Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 24, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation)
May 26, 2023	EX-99.1	Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update Exhibit 99.1 Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update ROCKVILLE, Md., May 26, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarter
May 25, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report UNDER Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 OR ☐ Transition Report UNDER Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-41488 SHUTTLE PHARMACEUTICAL
May 17, 2023	EX-99.1	Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference Exhibit 99.1 Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference ROCKVILLE, Md., May 17, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) (the “Company,” “Shuttle Pharmaceuticals”), announced
May 17, 2023	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 17, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation)
May 15, 2023	NT 10-Q	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read Instruction
May 11, 2023	EX-10.1	Amendment Agreement, dated May 10, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on May 11, 2023). Exhibit 10.1 Amendment Agreement This Amendment Agreement (this “Amendment”), dated as of May 10, 2023, is made by and between Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, in its capacity as the registered holder (the “Holder”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”) and each Guarantor signatory hereto. WHEREAS, the Company and the Buye
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 SHUTTLE PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of Incorporation)
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 SHUTTLE PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of Incorporation)
March 22, 2023	EX-99.2	Shuttle Pharmaceuticals Enter Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates Exhibit 99.2 Shuttle Pharmaceuticals Enter Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates ROCKVILLE, Md., March 22, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radia
March 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 SHUTTLE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of Incorporatio
March 22, 2023	EX-99.1	Press Release of Shuttle Pharmaceuticals Holdings, Inc. dated March 22, 2023 Exhibit 99.1
March 22, 2023	EX-10.2	Material Transfer Agreement, dated March 21, 2023, between Shuttle Pharmaceuticals, Inc. and Georgetown University (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on March 22, 2023). Exhibit 10.2 MATERIALS TRANSFER AGREEMENT This MATERIALS TRANSFER AGREEMENT (the “Agreement”) is made effective as of the last date of signature hereto (the “Effective Date”), by and between Georgetown University (“Georgetown”), a nonprofit institution of higher education organized as a non-stock corporation under federal charter and whose principle place of business is situated at 37th & O Street
March 22, 2023	EX-10.1	Research Agreement, dated March 16, 2023, between Shuttle Pharmaceuticals, Inc. and Georgetown University (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on March 22, 2023). Exhibit 10.1
March 22, 2023	EX-16.1	Letter from BF Borgers CPA PC to the Securities and Exchange Commission Exhibit 16.1 March 21, 2023 Securities and Exchange Commission Office of the Chief Accountant 100 F Street N.E. Washington, D.C. 20549 Re: Shuttle Pharmaceuticals Holdings, Inc. File Ref. No. 001-41488 We have read the statements made by Shuttle Pharmaceuticals Holdings, Inc., which we understand will be filed with the Commission, pursuant to Item 4.01 of Form 8-K, as part of Shuttle Pharmaceutica
March 15, 2023	EX-99.1	Press release, dated March 15, 2023.* Exhibit 99.1 Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update ROCKVILLE, Md., March 15, 2023 /PRNewswire/ — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing o
March 15, 2023	EX-10.44	Amended and Restated Insider Trading Policy, effective March 10, 2023 (incorporated by reference to Exhibit 10.44 to the Annual Report on Form 10-K filed March 15, 2023). Exhibit 10.44 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Amended and Restated Policy on Insider Trading This Amended and Restated Insider Trading Policy, effective March 10, 2023, provides the standards of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) on trading and causing the trading of the Company’s securities or securities of other publicly-traded companies while in possession of confiden
March 15, 2023	EX-10.46	Letter Agreement, dated March 11, 2023, between Shuttle Pharmaceuticals Holdings, Inc. and Alto Opportunity Master Fund, SPC – Segregated Portfolio B, as Collateral Agent (incorporated by reference to Exhibit 10.46 to the Annual Report on Form 10-K filed March 15, 2023). Exhibit 10.46 Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B 55 Post Road W., 2nd Floor Westport, CT 06880 March 12, 2023 Shuttle Pharmaceutical Holdings, Inc. 1 Research Court, Ste 450 Rockville, MD 20850 Re: Senior Secured Convertible Note dated January 11, 2023 (the “Note”) Ladies and Gentlemen: Reference is made to Section 15(q) of the Note. Capitalized terms used herein but
March 15, 2023	EX-10.45	Form of Executive Compensation Clawback Policy, effective March 10, 2023 (incorporated by reference to Exhibit 10.45 to the Annual Report on Form 10-K filed March 15, 2023). Exhibit 10.45 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. CLAWBACK POLICY I. Purpose Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) is establishing this clawback policy to appropriately align the interests of the executives of the Company, who have been designated as Executive Officers, with those of the Company. This policy has been approved by the Board and is effective as of the Effective Da
March 15, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:001-41488 Shuttle Pharmac
March 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 SHUTTLE PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of Incorporation
March 9, 2023	EX-10.1	Proposal for Service Agreement, dated March 7, 2023, between Shuttle Pharmaceuticals, Inc. and University of Iowa Pharmaceuticals (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed March 9, 2023). Exhibit 10.1
March 9, 2023	EX-99.1	Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial Exhibit 99.1 Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial ROCKVILLE, Md., March 9, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (R
March 6, 2023	SC 13G	SHPH / Shuttle Pharmaceuticals Holdings Inc / AFH Holding & Advisory, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 825693 (CUSIP Number) Amir F. Heshmatpour 17304 Preston Road, Suite 300 Dallas, Texas 75252 (310) 721-4391 With copies to: La
February 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 15, 2023 SHUTTLE PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 15, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State of Incorporation) (Primary Standard Ind
February 22, 2023	EX-10.1	Form of Director Offer Letter (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed February 22, 2023). Exhibit 10.1 Shuttle Pharmaceuticals Holdings Inc. One Research Court, Suite 450 Rockville, MD 20850 , 2023 Milton Brown, MD, PhD 2865 Martin’s Point Way Chesapeake, VA 24321 Re: Director Offer Letter Dear Dr. Brown: Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) thanks you for your continued service as a member of its board of directors (the “Board”). We believe that your background and e
February 13, 2023	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement SHUTTLE PHARMACEUTICALS HOLDINGS, I
February 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 6, 2023 SHUTTLE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 6, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State of Incorporation) (Primary Standard Indu
February 2, 2023	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement SHUTTLE PHARMACEUTICALS HOLDINGS, I
February 1, 2023	424B3	SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants PROSPECTUS Filed Pursuant to Section 424(b)(3) Registration No. 333-269414 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to the resale from time to time of (i) up to 9,744,605 shares of common stock underly
January 30, 2023	S-1/A	As filed with the Securities and Exchange Commission on January 30, 2023 As filed with the Securities and Exchange Commission on January 30, 2023 Registration No.
January 30, 2023	CORRESP	January 30, 2023 CORRESP 1 filename1.htm January 30, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Daniel Crawford Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 File No. 333-269414 Acceleration Request Requested Date: February 1, 2023 Requested Time: 9:00 AM Eas
January 27, 2023	CORRESP	January 27, 2023 CORRESP 1 filename1.htm January 27, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Daniel Crawford Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 (File No. 333-269414) Withdraw of Acceleration Request Dear Mr. Crawford: Reference is made to our le
January 26, 2023	EX-99.1	Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31 Exhibit 99.1 Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31 ROCKVILLE, Md., January 26, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced Anatoly Dritschilo, M.D., CEO
January 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 26, 2023 SHUTTLE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 26, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State of Incorporation) (Primary Standard Indu
January 25, 2023	S-1	As filed with the Securities and Exchange Commission on January 25, 2023 As filed with the Securities and Exchange Commission on January 25, 2023 Registration No.
January 25, 2023	EX-FILING FEES	Filing Fee Table* Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Shuttle Pharmaceuticals Holdings, Inc.
January 25, 2023	CORRESP	January 25, 2023 January 25, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Conlon Danberg Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 CIK No. 0001757499 File No. 333-269414 Acceleration Request Requested Date: January 27, 2023 Requested Time: 5:00 PM Eastern T
January 12, 2023	EX-10.5	Form of Intellectual Property Security Agreement, dated January 11, 2023 (incorporated by reference to Exhibit 10.5 to the Current Report on form 8-K filed January 12, 2023). Exhibit 10.5 FORM OF INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (“Agreement”) is entered into as of January 11, 2023, by and among (a) SHUTTLE PHARMACEUTICALS HOLDINGS INC., a Delaware corporation (the “Company”), (b) the Subsidiary Guarantors from time to time party hereto (such Subsidiary Guarantors, together with the Company, the “Grantors” and each a
January 12, 2023	EX-10.7	Form of Registration Rights Agreement, dated January 11, 2023 (incorporated by reference to Exhibit 10.7 to the Current Report on form 8-K filed January 12, 2023). Exhibit 10.7 Form OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 11, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and each of the several buyers signatory hereto (each such purchaser, a “Buyer” and, collectively, the “Buyers”). This Agreement is made pursuant to th
January 12, 2023	EX-10.6	Form of Subsidiary Guaranty (incorporated by reference to Exhibit 10.6 to the Current Report on form 8-K filed January 12, 2023). Exhibit 10.6 FORM OF SUBSIDIARY GUARANTY This SUBSIDIARY GUARANTY (this “Agreement”), dated as of January 11, 2023, is made by and among each of the undersigned Guarantors (collectively, the “Guarantors” and each of them a “Guarantor”) and Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, as agent for the Holders (as defined below) (in such capacity and together with any successor
January 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 11, 2023 SHUTTLE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 11, 2023 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State of Incorporation) (Primary Standard Indu
January 12, 2023	EX-10.2	Form of Note, dated January 11, 2023 (incorporated by reference to Exhibit 10.2 to the Current Report on form 8-K filed January 12, 2023). Exhibit 10.2 FORM OF SENIOR SECURED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE RE
January 12, 2023	EX-10.3	Form of Warrant, dated January 11, 2023 (incorporated by reference to Exhibit 10.3 to the Current Report on form 8-K filed January 12, 2023). EX-10.3 4 ex10-3.htm Exhibit 10.3 FORM OF WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS WARRANT NOR THE SECURITIES INTO WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
January 12, 2023	EX-99.1	Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants Exhibit 99.1 Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants ROCKVILLE, Md., Jan. 12, 2023 /PRNewswire/ — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing
January 12, 2023	EX-10.1	Form of Securities Purchase Agreement, dated January 11, 2023, between Shuttle Pharmaceuticals Holdings, Inc. and the investors named therein (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed January 12, 2023). Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 11, 2023, between Shuttle Pharmaceuticals Holdings, Inc, a Delaware corporation (the “Company”), and each buyer identified on the signature pages hereto (each, including its successors and assigns, a “Buyer” and collectively, the “Buyers”). WHEREAS, subject to the terms a
January 12, 2023	EX-10.4	Form of Security Agreement, dated January 11, 2023, between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC – Segregated Portfolio B (incorporated by reference to Exhibit 10.4 to the Current Report on form 8-K filed January 12, 2023). Exhibit 10.4 FORM OF SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of January 11, 2023 (as it may be amended or restated from time to time, this “Agreement”), is by and among Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), the Subsidiary Guarantors from time to time party hereto (such Subsidiary Guarantors, together with the Company, the “Debtors”), the holde
December 19, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 16, 2022 SHUTTLE PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 16, 2022 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State of Incorporation) (Primary Standard Ind
December 12, 2022	S-8	As filed with the Securities and Exchange Commission on December 12, 2022 As filed with the Securities and Exchange Commission on December 12, 2022 Registration No.
December 12, 2022	EX-FILING FEES	Fee Table* Exhibit 107 Calculation of Filing Fee Table Form S-8 Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A Common Stock Rules 457(c) and 457(h) 3,000,000 shares $ 2.
December 7, 2022	EX-99.1	Investor Deck, dated December 7, 2022. Exhibit 99.1
December 7, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 7, 2022 SHUTTLE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 7, 2022 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State of Incorporation) (Primary Standard Indu

SHPH / Shuttle Pharmaceuticals Holdings, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)